News for Healthier Living

ASCO: Targeted Drug Outperforms Chemotherapy for Patients with Hard-to-Treat Lung Cancer

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

May 29, 2026


May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026

May 20 2026

May 19 2026

May 18 2026

May 17 2026

May 16 2026

May 15 2026